Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O00587
UPID:
MFNG_HUMAN
Alternative names:
O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase
Alternative UPACC:
O00587; B4DLT6; O43730; Q504S9
Background:
Beta-1,3-N-acetylglucosaminyltransferase manic fringe, also known as O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, plays a pivotal role in the post-translational modification of Notch molecules. It initiates the elongation of O-linked fucose residues on EGF-like repeats in the extracellular domain, crucial for Notch signaling pathway modulation. This enzyme specifically enhances or inhibits NOTCH1 activity through the modification of O-fucose residues, influencing cell fate decisions.
Therapeutic significance:
Understanding the role of Beta-1,3-N-acetylglucosaminyltransferase manic fringe could open doors to potential therapeutic strategies. Its involvement in the Notch signaling pathway, a key regulator of cell differentiation and proliferation, highlights its potential as a target for modulating disease-related signaling cascades.